Efficacy of a bivalent killed whole-cell cholera vaccine over five years: A re-analysis of a cluster-randomized trial
BMC Infectious Diseases Feb 27, 2018
Fong Y, et al. - Given the feasibility of oral cholera vaccine (OCV) in preventing or mitigating cholera outbreaks, researchers sought to assess better understanding of the vaccine’s efficacy among different age groups and how rapidly its protection wanes. They observed the vaccine efficacy of 38% for those vaccinated from ages 1 to under 5 years old, 85% for those 5 to under 15 years, and 69% for those vaccinated at ages 15 years and older. During the trial, efficacy did not appear to wane among adult vaccinees, but there was insufficient data to assess the waning of efficacy among child vaccinees. Findings there revealed a statistically significant difference in OCV efficacy when the vaccine was administered to children under 5 years old vs children 5 years and older.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries